 |
We are advised by Antengene Corporation Limited that journalists and other readers should disregard the news release, Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug, issued 28-Jul-2025 over PR Newswire.
source: Antengene Corporation Limited
【你點睇？】本港2025年本港復甦緩慢，經濟受到衝擊，亦發生多宗社會重大事件。你點睇2025年的香港？展望2026年，你最期待哪方面？► 立即投票
